GlobeNewswire by notified

Beter Bed Holding announces AGM and provides update on current developments – good start to the year 2022

Share

Today, Beter Bed Holding N.V. (BBH) – the Netherlands’ largest sleep specialist in retail, wholesale and B2B – has published the notice and agenda for its Annual General Meeting (AGM) to be held on Wednesday, 11 May 2022. Further information on the AGM is available on the company’s website www.beterbedholding.com.

During the AGM, BBH will look back on the results achieved over 2021, and update the shareholders on the current developments. 2021 began and concluded with temporary store closures, however the impact has been managed in the remainder of the year and BBH has been able to show growth in sales, EBITDA, EBIT and net profit for the 2021 financial year. This put the Company in a strong starting position for 2022.

John Kruijssen, CEO, comments:
"I am proud of how our organisation performed in 2021. Through the pandemic, we were always open for business – even with our stores closed successfully connecting with people in new ways, and serving our growing customer base with our innovative range of sleep solutions.

The strategic developments in 2021 contributed to our strong financial results, reflecting the underlying strength of our strategic transformation and putting us in a good starting position for 2022. Our company is in good commercial and financial shape. As a result of our solid financial position and strong results, we will propose a dividend payout of € 0.15 per ordinary share at the AGM, a strong signal of confidence in our future.

We are set to ramp up investments in accordance with our 2025 Strategy and continue to build on our 'Sleep better, live better' purpose, with the aim to attain our ambitious growth targets.

Update first quarter 2022
Despite the mandatory store closures for the first two weeks of 2022 in the Netherlands, which has already started in the second half of December 2021, BBH started the year strongly. Year to date we show a solid performance. Currently, all stores are open without COVID-19 restrictions and order intake is well above pre-COVID level.

Although measures have eased, COVID-19 is still present: it limits availability of staff, commodity prices are high and supply chain issues persist. We are closely monitoring recent developments in Europe, which could have an impact on the global economy. Our thoughts go out to the people in Ukraine. At present, we see limited impact in our supply chain, but we continue to be in close contact with our partners, have re-addressed certain commodity sources, and deliberately maintain safety stock levels to minimise potential impact on deliveries to our customers. We anticipate that the current disruptions will take some time to normalise and we continue to retain focus on cost control, disciplined capital spend and strict cash flow management.

Despite this turbulent environment, the implementation of our 2025 Strategy is in full swing and the Company is in a good shape. We will further increase our CAPEX in 2022 to attain our ambitious growth targets towards 2025.


Further update
BBH will publish its Q1 trading update on 22 April 2022.


AboutBeterBedHolding
Beter Bed Holding (BBH) is the Netherlands’ leading sleep specialist in retail, wholesale and B2B.

Our mission is simple. Webelievethatthebetterwesleep,thehappier,healthierandmoreproductiveweare.Andwewon’trestuntileveryonegetsthehigh-qualitysleeptheydeserve.

Listed on Euronext Amsterdam, BBH operates the successful retail brands Beter Bed, Beddenreus, the new subscription brand Leazzzy and the digital organisation LUNEXT. In addition, through its subsidiary DBC International, BBH has a wholesale business in branded products in the bedroom furnishings sector, which includes the well-known international brand M line.

With 4 distribution centres, a fleet of 80 vehicles, 134 stores, a fast-growing online presence, and a wholesale company our team of over 1,000 dedicated employees generated € 214.2 million revenue in 2021.

Providing expert sleep advice is at the very heart of our strategy, and thanks to our revolutionary ‘Beter Slapen ID’ tool, our sleep consultants help customers to get the perfect night’s sleep. BBH is proud that M line is the official sleep    supplier of AFC Ajax, TeamNL, Jumbo-Visma, NOC*NSF and the KNVB.


For more information
Press enquiries: Uneke Dekkers / CFF Communications
T +31 (0)20 575 4010 or M +31 (0)6 50261626
E uneke.dekkers@cffcommunications.nl


For the Pdf version of the press release please click on the link below. Press photos can be downloaded here.


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Changes in financial results publication18.5.2022 18:01:16 CEST | Press release

PRFoods AS declares that 2021/2022 financial year 9 months unaudited results will be published, according to Stock Exchange rules no later than two months after end of the reporting period, 31.5.2022. Although interim report will be unaudited, PRFoods has required a third party assessment of the impact of sale of Heimon Kala Oy, taking into account that final purchase price is dependent on certain conditions subsequent presumed to be met before publication. Indrek Kasela AS PRFoods Member of the Management Board Phone: +372 452 1470 investor@prfoods.ee www.prfoods.ee

PRESS RELEASE: NACON: WRC GENERATIONS: THE MOST COMPLETE RALLY GAME IS COMING IN OCTOBER!18.5.2022 17:46:00 CEST | Press release

WRC GENERATIONS: THE MOST COMPLETE RALLY GAME IS COMING IN OCTOBER! Lesquin, 18th May 2022 - NACON and the studio KT Racing are pleased to announce their new rally game, WRC Generations, the official video game of the FIA World Rally Championship, scheduled for release in Autumn 2022 on PlayStation®4, PlayStation®5, Xbox One, Xbox Series X|S, Nintendo Switch and Steam for PC. The result of 7 years of collaboration with legendary drivers, who have already made WRC 10 and WRC 9 the references of the genre, the latest entry in the series is an authentic and comprehensive rally racing simulation, giving players the chance to drive powerful cars in the most famous rallies of all time! Check out the announcement trailer for WRC Generations: [link] An unrivalled level of realism Never before have games come this close to the real-life World Rally Championship! Hailed by both critics and professionals, this year's WRC simulation has been reinforced with numerous improvements and optimisations

PRESS RELEASE: NACON PRESENTS AN AMBITIOUS LINEUP AND ANNOUNCES TWO NEW GAMES18.5.2022 17:45:00 CEST | Press release

NACON PRESENTS AN AMBITIOUS LINEUP AND ANNOUNCES TWO NEW GAMES NACON has confirmed its status as a major mid-publisher and creator of standard-setting accessories Paris (France), 18 May 2022 – The latest edition of Bigben Week opened its doors on Monday. This major event for the group is the perfect occasion to present its products and objectives to the media and international partners. NACON, the group's gaming brand, held a press conference to announce all of its news and to explain how it is changing. The last time the event was held – in 2019, due to the health crisis – BIGBEN presented its soaring ambitions for the years to come. Bigben Week is an opportunity to highlight the company's strong growth over the last three years along with the major changes it has undergone. AN EFFECTIVE STRATEGY NACON’s March 2020 listing on the stock market raised more than €100 million, reinforcing the company's ambitions and resources. Over the course of three years, NACON acquired no fewer than 9

FDA beviljar särläkemedelsstatus för tasquinimod vid behandling av myelofibros18.5.2022 15:00:00 CEST | Pressemelding

Lund 18 maj 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) meddelade idag att amerikanska Food and Drug Administration (FDA) har beviljat särläkemedelsstatus för tasquinimod vid behandling av myelofibros. "Särläkemedelsstatus som FDA tilldelat för tasquinimod i myelofibros utgör ett viktigt steg framåt för Active Biotech", säger Helén Tuvesson, VD Active Biotech. "Det öppnar en viktig regulatorisk väg och ger oss potential att snabbt avancera utvecklingen av tasquinimod i denna patientpopulation.” FDAs Orphan Drug Designation program ger särläkemedelsstatus för läkemedelskandidater avsedda för säker och effektiv behandling, diagnos eller förebyggande av ovanliga sjukdomar som drabbar färre än 200.000 människor i USA. Denna särläkemedelsstatus ger 7 års marknadsexklusivitet vid marknadsgodkännande samt vissa andra fördelar. I februari 2022 ingick Active Biotech ett exklusivt licensavtal med Oncode Institute i Nederländerna, som verkar på uppdrag av Erasmus University Medical Center (

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis18.5.2022 15:00:00 CEST | Press release

Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the development of tasquinimod in this patient population.” The FDA Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnoses or prevention of rare diseases or disorders that affects fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives. In February 2022, Active Biotech entered into an exclusive lice